IRIS
MOR, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.310
AS - Asia 11.684
EU - Europa 9.304
SA - Sud America 1.604
AF - Africa 593
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 36.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.934
SG - Singapore 4.203
CN - Cina 3.225
IT - Italia 1.989
VN - Vietnam 1.811
FI - Finlandia 1.440
IE - Irlanda 1.295
BR - Brasile 1.250
SE - Svezia 1.146
DE - Germania 946
HK - Hong Kong 858
UA - Ucraina 652
BD - Bangladesh 402
ZA - Sudafrica 397
FR - Francia 393
NL - Olanda 359
TR - Turchia 288
GB - Regno Unito 287
CA - Canada 240
IN - India 208
RU - Federazione Russa 189
AT - Austria 188
AR - Argentina 122
CI - Costa d'Avorio 90
BE - Belgio 86
JP - Giappone 86
IQ - Iraq 76
MX - Messico 75
PL - Polonia 75
ES - Italia 73
KR - Corea 73
ID - Indonesia 66
EC - Ecuador 57
CZ - Repubblica Ceca 49
PK - Pakistan 47
PH - Filippine 46
TH - Thailandia 41
CO - Colombia 39
VE - Venezuela 39
JO - Giordania 29
CL - Cile 28
LT - Lituania 28
MA - Marocco 28
UZ - Uzbekistan 28
PY - Paraguay 25
SA - Arabia Saudita 22
TW - Taiwan 20
KE - Kenya 18
MY - Malesia 18
UY - Uruguay 16
PE - Perù 15
IL - Israele 14
NP - Nepal 14
RO - Romania 14
AZ - Azerbaigian 13
TN - Tunisia 13
ET - Etiopia 12
HU - Ungheria 12
EG - Egitto 11
HN - Honduras 11
HR - Croazia 11
OM - Oman 11
PA - Panama 10
IR - Iran 9
BO - Bolivia 8
BY - Bielorussia 8
DZ - Algeria 8
JM - Giamaica 8
KG - Kirghizistan 8
LB - Libano 8
PS - Palestinian Territory 8
SY - Repubblica araba siriana 8
AL - Albania 7
AU - Australia 7
DO - Repubblica Dominicana 7
EU - Europa 7
KZ - Kazakistan 7
RS - Serbia 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
CH - Svizzera 6
CR - Costa Rica 6
NI - Nicaragua 6
NO - Norvegia 6
EE - Estonia 5
MD - Moldavia 5
QA - Qatar 5
AO - Angola 4
CY - Cipro 4
GE - Georgia 4
LU - Lussemburgo 4
LV - Lettonia 4
SI - Slovenia 4
SN - Senegal 4
BH - Bahrain 3
GR - Grecia 3
GY - Guiana 3
MN - Mongolia 3
SK - Slovacchia (Repubblica Slovacca) 3
TJ - Tagikistan 3
Totale 36.473
Salva come PNG Salva come JPEG
Città #
Singapore 2.107
Ashburn 1.537
Chandler 1.285
Dublin 1.285
San Jose 1.231
Dallas 994
Hong Kong 811
Santa Clara 775
Beijing 759
Jacksonville 754
Parma 576
Ho Chi Minh City 565
Dearborn 456
Ann Arbor 440
Boardman 439
Hanoi 388
Johannesburg 371
Los Angeles 329
Nanjing 319
New York 303
Lauterbourg 250
Princeton 248
Munich 241
Izmir 233
Shanghai 226
Wilmington 190
Hefei 179
Helsinki 162
San Mateo 162
Vienna 152
Milan 131
São Paulo 126
Toronto 126
Bremen 113
Columbus 110
Shenyang 109
Buffalo 102
Moscow 98
Nanchang 93
Abidjan 90
Jinan 88
Bologna 86
Council Bluffs 86
Hebei 86
Kunming 85
Haiphong 79
Turku 77
Brussels 76
Da Nang 76
The Dalles 72
Frankfurt am Main 70
Tokyo 70
Seattle 65
London 64
Düsseldorf 63
Changsha 62
Des Moines 60
Warsaw 58
Guangzhou 55
Montreal 52
Brooklyn 50
Jiaxing 49
Chicago 47
Tianjin 47
Houston 46
Jakarta 46
Modena 46
Pune 45
Seoul 45
Phoenix 43
Brescia 40
Denver 39
Orem 39
Rio de Janeiro 38
Woodbridge 38
Atlanta 37
Rome 37
Stockholm 36
Chennai 35
Fremont 33
Nuremberg 33
San Francisco 32
Naples 31
Baghdad 30
Belo Horizonte 30
Norwalk 30
Zhengzhou 29
Dhaka 26
Amman 25
Biên Hòa 25
Can Tho 25
Hangzhou 25
Mexico City 25
Poplar 25
Amsterdam 24
Grafing 24
Ankara 23
Brno 22
Palermo 22
Tashkent 22
Totale 21.659
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 278
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 264
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 251
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 251
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 244
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 239
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 234
2-Aminobenzimidazoles as new potent H3-antagonists 226
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 219
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 219
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 219
Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats 218
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 217
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 215
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 214
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 210
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 208
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 207
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 206
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 203
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 203
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 201
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 198
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 198
Analysis of illicit dietary supplements sold in the Italian market: Identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. 198
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Aminobenzimidazoles as new potent H3-antagonists 196
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 195
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 194
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 194
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 192
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 191
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 191
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 189
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 185
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 181
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 181
5-benzylidene-hydantoins as new inhibitors of cell proliferation 179
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 178
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo 178
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 177
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 177
3-Aminoazetidin-2-one Derivatives asN-Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration 177
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 177
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 176
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 176
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 176
4-(1,2-benzisothiazol-3-)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 174
Functional modulation of the human gut microbiome by bacteria vehicled by cheese 173
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 170
2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists. 170
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 169
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 168
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 166
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 165
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 163
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 163
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 162
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility 162
N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability 162
Steps towards sustainable solid phase peptide synthesis: use and recovery ofN-octyl pyrrolidone 162
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 161
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 161
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 159
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 158
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 156
Chiral NMR discrimination of the diastereoisomeric salts of the H(3)-antagonist 2-[3-(1H-imidazol-4-ylmethyl)piperidin-1-yl]-1H-benzimidazole. 155
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 154
Antioxidant and cytoprotective activity of indole derivatives related to melatonin 153
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 153
Palladium Catalyst Recycling for Heck-Cassar-Sonogashira Cross-Coupling Reactions in Green Solvent/Base Blend 153
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 151
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 151
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 151
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 150
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 150
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 149
Brain Pharmacokinetics of Non-Imidazole Biphenyl H3 Receptor Antagonists: a Liquid Chromatography/Electrospray-Mass Spectrometry and ex vivo Binding Study in Rats 149
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 149
Mannich base derivatives as novel EGFR irreversible inhibitors 149
Biological studies on 1,2-benzisothiazole derivatives. V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation 149
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 148
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 148
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 148
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 147
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 147
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 146
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 146
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 145
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 145
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 145
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 145
Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. 144
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 143
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 143
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 142
Totale 18.117
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.311
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.311
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202157 0 0 0 0 0 0 0 0 0 0 0 57
2021/20221.311 24 37 14 121 85 40 149 175 91 102 90 383
2022/20235.095 551 503 311 392 486 607 46 313 1.575 60 188 63
2023/20241.980 109 148 56 68 145 457 166 159 78 124 201 269
2024/20256.618 169 350 436 424 600 739 303 354 836 650 590 1.167
2025/202614.736 1.235 1.584 1.832 1.405 1.951 817 1.557 449 1.750 1.065 662 429
Totale 36.900